Product on the market
CarciReagent® is a commercialised IVD medical device for self-testing with active D2C and distribution channels.
Investor relations
The public website opens the story. The transaction detail remains private.
CNEU MEDICAL INVEST conducts individual investor discussions within a private growth round. Specific terms and transaction documentation are provided only after investor access is approved.
Investment thesis
Not a concept on paper. The next stage of an operating MedTech business.
The investor story is built around an existing product, rapid commercial growth, an international distribution pipeline and defined growth milestones.
Commercial momentum
Management reports revenue growth from CZK 2.064m in 2023 to CZK 48.946m in 2025.
International expansion
The distribution network and commercial pipeline span European and non-European markets at different stages of activation.
Further catalysts
IVDR, product-development completion and the planned veterinary platform create further potential milestones.
Why capital now
Capital is intended to accelerate defined milestones, not finance a concept.
The public website shows the principal capital priorities. Detailed budgets, round terms and transaction documentation remain in the private investor area.
Completion of product development
Close key development stages and prepare for further commercialisation.
IVDR and regulatory development
Fund regulatory steps associated with further European development.
Veterinary platform
Complete development and certification of the planned product for dogs.
Commercialisation and working capital
International expansion, commercial scale, manufacturing and working capital.
Investor relations
A controlled process from interest to due diligence
Registration is not an investment subscription. It starts an individual investor conversation and may lead to access to detailed materials.
Investor access request
Manual review and management call
NDA where appropriate
Investor deck and data room
Due diligence
Term sheet and closing
Investor Access
Detailed investment materials are provided individually.
Specific round economics, the detailed financial model, data room and transaction documentation are available only after registration and manual access review.
Public information is presented in line with available source materials. Forecasts are management estimates and future results are not guaranteed.